Free shipping on all orders over $ 500

LX-4211

Cat. No. M5249
LX-4211 Structure
Synonym:

Sotagliflozin

Size Price Availability Quantity
5mg USD 108  USD120 In stock
10mg USD 180  USD200 In stock
25mg USD 360  USD400 In stock
50mg USD 612  USD680 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

In vitro: LX4211 inhibits [14C]AMG uptake with IC50 of 62.0 nM for mouse SGLT1 and 0.6 nM for mouse SGLT2, respectively. In vivo: In mice, LX4211 (60 mg/kg, p.o.) reduces intestinal glucose absorption by inhibiting SGLT1, resulting in net increases in GLP-1 and PYY release and decreases in GIP release and blood glucose excursions. In nonobese diabetes-prone mice with type 1 diabetes, Sotagliflozin (30 mg/kg) significantly improves glycemic control, without increasing the rate of hypoglycemia measurements.

Protocol
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models Male albino C57BL/6-Tyrc-Brd mice
Formulation Aqueous 0.1% v/v Tween 80
Dosages ~60 mg/kg
Administration p.o.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 424.94
Formula C21H25ClO5S
CAS Number 1018899-04-1
Purity >98%
Solubility 84 mg/mL in DMSO
Storage at -20°C
References

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.
Powell DR, et al. Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7. PMID: 25759591.

LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
Powell DR, et al. J Pharmacol Exp Ther. 2013 May;345(2):250-9. PMID: 23487174.

Related SGLT Products
Tofogliflozin (hydrate)

Tofogliflozin (CSG-452) hydrate is a potent and highly specific sodium-glucose co-transporter 2(SGLT2) inhibitor with IC50 value of 2.9 nM.

Luseogliflozin

Luseogliflozin is a SGLT2 inhibitor, it reduced reabsorption of renal filtered glucose and decreased renal glucose threshold (RTG) in urine to increase urinary glucose excretion.

LX2761

LX2761 is a locally acting SGLT1 and SGLT2 inhibitor in vitro with IC50 values of 2.2 nM and 2.7 nM for hSGLT1 and hSGLT2, respectively.

Canagliflozin hemihydrate

Canagliflozin hemihydrate (JNJ-28431754; TA 7284) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM.

Dapagliflozin ((2S)-1,2-propanediol, hydrate)

Dapagliflozin(BMS512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) is in development for the treatment of type 2 diabetes mellitus (T2DM).

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: LX-4211, Sotagliflozin supplier, SGLT, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.